Background During the United Kingdom Prospective Diabetes Study(UKPDS), patients with type 2 diabetes mellitus who receivedintensive glucose therapy had a lower risk of microvascularcomplications than did those receiving conventional dietarytherapy. We conducted post-trial monitoring to determine whetherthis improved glucose control persisted and whether such therapyhad a long-term effect on macrovascular outcomes.
Methods Of 5102 patients with newly diagnosed type 2 diabetes,4209 were randomly assigned to receive either conventional therapy(dietary restriction) or intensive therapy (either sulfonylureaor insulin or, in overweight patients, metformin) for glucosecontrol. In post-trial monitoring, 3277 patients were askedto attend annual UKPDS clinics for 5 years, but no attemptswere made to maintain their previously assigned therapies. Annualquestionnaires were used to follow patients who were unableto attend the clinics, and all patients in years 6 to 10 wereassessed through questionnaires. We examined seven prespecifiedaggregate clinical outcomes from the UKPDS on an intention-to-treatbasis, according to previous randomization categories.
Results Between-group differences in glycated hemoglobin levelswere lost after the first year. In the sulfonylurea–insulingroup, relative reductions in risk persisted at 10 years forany diabetes-related end point (9%, P=0.04) and microvasculardisease (24%, P=0.001), and risk reductions for myocardial infarction(15%, P=0.01) and death from any cause (13%, P=0.007) emergedover time, as more events occurred. In the metformin group,significant risk reductions persisted for any diabetes-relatedend point (21%, P=0.01), myocardial infarction (33%, P=0.005),and death from any cause (27%, P=0.002).
Conclusions Despite an early loss of glycemic differences, acontinued reduction in microvascular risk and emergent riskreductions for myocardial infarction and death from any causewere observed during 10 years of post-trial follow-up. A continuedbenefit after metformin therapy was evident among overweightpatients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837
[controlled-trials.com]
.)
Source Information
From the Diabetes Trials Unit (R.R.H., S.K.P., M.A.B.), the Division of Public Health and Primary Health Care (H.A.W.N.), and the National Institute of Health Research (NIHR) School for Primary Care Research (H.A.W.N.), Oxford Centre for Diabetes, Endocrinology, and Metabolism (R.R.H., S.K.P., M.A.B., D.R.M., H.A.W.N.); and the NIHR Oxford Biomedical Research Centre (R.R.H., D.R.M., H.A.W.N.) — both in Oxford, United Kingdom. This article (10.1056/NEJMoa0806470) was published at www.nejm.org on September 10, 2008.
Address reprint requests to Dr. Holman at the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom, or at rury.holman{at}dtu.ox.ac.uk.
Lund, S. S, Tarnow, L., Frandsen, M., Nielsen, B. B, Hansen, B. V, Pedersen, O., Parving, H.-H., Vaag, A. A
(2009). Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ
339: b4324-b4324
[Abstract][Full Text]
Song, S.H., Hardisty, C.A.
(2009). Early onset type 2 diabetes mellitus: a harbinger for complications in later years--clinical observation from a secondary care cohort. QJM
102: 799-806
[Abstract][Full Text]
Zoungas, S., de Galan, B. E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., MacMahon, S., Marre, M., Neal, B., Patel, A., Woodward, M., Chalmers, J., on behalf of the ADVANCE Collaborative Group,
(2009). Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial. Diabetes Care
32: 2068-2074
[Abstract][Full Text]
Reaven, P. D., Moritz, T. E., Schwenke, D. C., Anderson, R. J., Criqui, M., Detrano, R., Emanuele, N., Kayshap, M., Marks, J., Mudaliar, S., Harsha Rao, R., Shah, J. H., Goldman, S., Reda, D. J., McCarren, M., Abraira, C., Duckworth, W., for the Veterans Affairs Diabetes Trial,
(2009). Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis. Diabetes
58: 2642-2648
[Abstract][Full Text]
Raz, I.
(2009). Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Dilemmas in clinical practice. Diabetes Care
32: S149-S150
[Full Text]
Swinnen, S. G., Hoekstra, J. B., DeVries, J. H.
(2009). Insulin Therapy for Type 2 Diabetes. Diabetes Care
32: S253-S259
[Full Text]
Bretzel, R. G., Eckhard, M., Landgraf, W., Owens, D. R., Linn, T.
(2009). Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care
32: S260-S265
[Full Text]
Chiasson, J.-L.
(2009). Early Insulin Use in Type 2 Diabetes: What are the cons?. Diabetes Care
32: S270-S274
[Full Text]
Hanefeld, M., Bornstein, S. R., Pistrosch, F.
(2009). Shifting the Disease Management Paradigm From Glucose: What are the cons?. Diabetes Care
32: S353-S356
[Full Text]
Roden, M.
(2009). Optimal Insulin Treatment in Type 2 Diabetes. NEJM
361: 1801-1803
[Full Text]
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., Paul, S. K., the 4-T Study Group,
(2009). Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. NEJM
361: 1736-1747
[Abstract][Full Text]
McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z.
(2009). Medicare Spending for Previously Uninsured Adults. ANN INTERN MED
0: 0000605-200912010-00149v1-E-149
[Abstract][Full Text]
Bailey, C. J., Blonde, L., Del Prato, S., Leiter, L. A., Nesto, R., Global Partnership for Effective Diabetes Manageme,
(2009). What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diabetes and Vascular Disease Research
6: 283-287
[Abstract]
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., for the Albiglutide Study Group,
(2009). Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care
32: 1880-1886
[Abstract][Full Text]
Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J. H., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebel, R. J., Yawn, B. P., Yapuncich, V., Breslin, M. A., Pencille, L., Smith, S. A.
(2009). The Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial. Arch Intern Med
169: 1560-1568
[Abstract][Full Text]
Kosiborod, M., Inzucchi, S. E., Krumholz, H. M., Masoudi, F. A., Goyal, A., Spertus, J. A.
(2009). Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?--Reply. Arch Intern Med
169: 1637-1638
[Full Text]
Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., Ridker, P. M
(2009). Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial. JAMA
302: 1186-1194
[Abstract][Full Text]
Flegel, K.
(2009). Controlling the complications of diabetes: It's about the sugar. CMAJ
181: 357-357
[Full Text]
Flegel, K.
(2009). La maitrise des complications du diabete: une question de sucre. CMAJ
181: E106-E107
[Full Text]
Eggleston, K. N., Shah, N. D., Smith, S. A., Wagie, A. E., Williams, A. R., Grossman, J. H., Berndt, E. R., Long, K. H., Banerjee, R., Newhouse, J. P.
(2009). The Net Value of Health Care for Patients With Type 2 Diabetes, 1997 to 2005. ANN INTERN MED
151: 386-393
[Abstract][Full Text]
Cruickshank, J. K., Banerjee, M.
(2009). Pregnancy glycemia to vascular risk: Nonglycemic diabetes?. CMAJ
181: 361-362
[Full Text]
Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., He, J.
(2009). Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. ANN INTERN MED
151: 394-403
[Abstract][Full Text]
Millett, C., Bottle, A., Ng, A., Curcin, V., Molokhia, M., Saxena, S., Majeed, A.
(2009). Pay for perfomance and the quality of diabetes management in individuals with and without co-morbid medical conditions. JRSM
102: 369-377
[Abstract][Full Text]
Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., Porter, L.
(2009). Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes. Diabetes Care
32: 1577-1582
[Abstract][Full Text]
Wilding, J. P.H., Norwood, P., T'joen, C., Bastien, A., List, J. F., Fiedorek, F. T.
(2009). A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care
32: 1656-1662
[Abstract][Full Text]
Huang, E. S., Basu, A., O'Grady, M. J., Capretta, J. C.
(2009). Using Clinical Information To Project Federal Health Care Spending. Health Aff (Millwood)
28: w978-w990
[Abstract][Full Text]
Lafata, J. E., Dobie, E. A., Divine, G. W., Ulcickas Yood, M. E., McCarthy, B. D.
(2009). Sustained Hyperglycemia Among Patients With Diabetes: What matters when action is needed?. Diabetes Care
32: 1447-1452
[Abstract][Full Text]
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., Mogensen, C.-E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancia, G., Woodward, M., MacMahon, S., Chalmers, J., on behalf of the ADVANCE Collaborative Group,
(2009). Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. J. Am. Soc. Nephrol.
20: 1813-1821
[Abstract][Full Text]
Lasserson, D S
(2009). Initial management of suspected transient cerebral ischaemia and stroke in primary care: implications of recent research. Postgrad. Med. J.
85: 422-427
[Abstract][Full Text]
Laurent, S., Briet, M., Boutouyrie, P.
(2009). Large and Small Artery Cross-Talk and Recent Morbidity-Mortality Trials in Hypertension. Hypertension
54: 388-392
[Full Text]
Weinrauch, L. A., Lewis, E. F.
(2009). Aiming for the best control of glycemia in patients with heart failure and type 2 diabetes the "sweet spot".. J Am Coll Cardiol
54: 429-431
[Full Text]
Preis, S. R., Pencina, M. J., Hwang, S.-J., D'Agostino, R. B. Sr, Savage, P. J., Levy, D., Fox, C. S.
(2009). Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. Circulation
120: 212-220
[Abstract][Full Text]
Luan, R., Liu, S., Yin, T., Lau, W. B., Wang, Q., Guo, W., Wang, H., Tao, L.
(2009). High glucose sensitizes adult cardiomyocytes to ischaemia/reperfusion injury through nitrative thioredoxin inactivation. Cardiovasc Res
83: 294-302
[Abstract][Full Text]
Narendran, P.
(2009). Cardiovascular benefit of intensive glucose control: approaching closure. British Journal of Diabetes & Vascular Disease
9: 175-176
[Abstract]
Wilding, J.
(2009). Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. British Journal of Diabetes & Vascular Disease
9: 177-185
[Abstract]
Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A.
(2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol
161: 1-9
[Abstract][Full Text]
O'Connor, P. J., Crain, A. L., Rush, W. A., Hanson, A. M., Fischer, L. R., Kluznik, J. C.
(2009). Does Diabetes Double the Risk of Depression?. Ann Fam Med
7: 328-335
[Abstract][Full Text]
van Biesen, W., Van Laecke, S., Vanholder, R.
(2009). Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrol Dial Transplant
24: 2286-2287
[Full Text]
Fonseca, V., Inzucchi, S. E., Ferrannini, E.
(2009). Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. Diabetes Care
32: 1344-1345
[Full Text]
Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., Izquierdo, R. E., Ebner, S., Silver, S., Petkova, E., Kong, J., Eimicke, J. P., IDEATel Consortium,
(2009). A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. J. Am. Med. Inform. Assoc.
16: 446-456
[Abstract][Full Text]
Despres, J.-P.
(2009). Targeting abdominal obesity and the metabolic syndrome to manage cardiovascular disease risk. Heart
95: 1118-1124
[Full Text]
Marwick, T. H., Hordern, M. D., Miller, T., Chyun, D. A., Bertoni, A. G., Blumenthal, R. S., Philippides, G., Rocchini, A., on behalf of the American Heart Association Exerci,
(2009). Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk: A Scientific Statement From the American Heart Association. Circulation
119: 3244-3262
[Full Text]
Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., Iskandrian, A. E.
(2009). The scope of coronary heart disease in patients with chronic kidney disease.. J Am Coll Cardiol
53: 2129-2140
[Abstract][Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: YES. cfp
55: 580-582
[Full Text]
Wilson, G., Perry, T.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: NO. cfp
55: 581-583
[Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: OUI. cfp
55: 584-588
[Full Text]
Wilson, G., Perry, T.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: NON. cfp
55: 585-588
[Full Text]
Booth, G. L
(2009). Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. Evid. Based Med.
14: 73-73
[Full Text]
Bloomgarden, Z. T.
(2009). Cardiovascular Disease, Neuropathy, and Retinopathy. Diabetes Care
32: e64-e68
[Full Text]
Bartnik, M., Cosentino, F.
(2009). Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. Eur Heart J
30: 1301-1304
[Full Text]
Hall, G. M., Nicholson, G.
(2009). Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?. Anesth. Analg.
108: 1727-1730
[Full Text]
Griffin, S., Graffy, J.
(2009). New QOF glycaemia targets are achievable and evidence based. BMJ
338: b1915-b1915
[Full Text]
Banarer, S., Luan, F. L., Duckworth, W. C., Moritz, T., Abraira, C.
(2009). Glucose Control and Vascular Complications in Type 2 Diabetes. NEJM
360: 2031-2032
[Full Text]
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., El-Osta, A.
(2009). Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes
58: 1229-1236
[Abstract][Full Text]
Crasto, W, Jarvis, J, Khunti, K, Davies, M J
(2009). New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad. Med. J.
85: 257-267
[Abstract][Full Text]
Cheng, A. Y.Y., Leiter, L. A.
(2009). Cardiovascular risk and glycemic control. CMAJ
180: 907-908
[Full Text]
Kahn, S. E.
(2009). Glucose Control in Type 2 Diabetes: Still Worthwhile and Worth Pursuing. JAMA
301: 1590-1592
[Full Text]
Nathan, D. M.
(2009). Progress in Diabetes Research--What's Next. JAMA
301: 1599-1601
[Full Text]
Sanz, J., Moreno, P. R., Fuster, V.
(2009). The year in atherothrombosis.. J Am Coll Cardiol
53: 1326-1337
[Full Text]
Sherifali, D., Punthakee, Z.
(2009). To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evid. Based Med.
14: 34-37
[Full Text]
O'Connor, P. J., Sperl-Hillen, J. M.
(2009). The Role of Diabetes Educators in the Medical Home. Diabetes Spectr.
22: 124-126
[Full Text]
Younis, N., Soran, H., Hassanein, M.
(2009). Cardiovascular disease and intensive glucose lowering in type 2 diabetes. QJM
102: 293-296
[Full Text]
List, J. F., Woo, V., Morales, E., Tang, W., Fiedorek, F. T.
(2009). Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes. Diabetes Care
32: 650-657
[Abstract][Full Text]
Diabetes Prevention Program Research Group,
(2009). Changes in Albumin Excretion in the Diabetes Prevention Program. Diabetes Care
32: 720-725
[Abstract][Full Text]
Katz, R., Budoff, M. J., Takasu, J., Shavelle, D. M., Bertoni, A., Blumenthal, R. S., Ouyang, P., Wong, N. D., O'Brien, K. D.
(2009). Relationship of Metabolic Syndrome With Incident Aortic Valve Calcium and Aortic Valve Calcium Progression: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes
58: 813-819
[Abstract][Full Text]
Helms, K. L, Kelley, K. W
(2009). Insulin Glulisine: An Evaluation of Its Pharmacodynamic Properties and Clinical Application. The Annals of Pharmacotherapy
43: 658-668
[Abstract][Full Text]
Sheehy, A. M., Coursin, D. B., Gabbay, R. A.
(2009). Revisiting Screening for Type 2 Diabetes Mellitus: To Screen or Not to Screen, That Is the Question-Reply-I. Mayo Clin Proc.
84: 384-385
[Full Text]
Jenkins, D. J.A., Sievenpiper, J. L., Pauly, D., Sumaila, U. R., Kendall, C. W.C., Mowat, F. M.
(2009). Are dietary recommendations for the use of fish oils sustainable?. CMAJ
180: 633-637
[Full Text]
Lehman, R., Krumholz, H. M
(2009). Tight control of blood glucose in long standing type 2 diabetes. BMJ
338: b800-b800
[Full Text]
Song, S. H, Gray, T. A
(2009). Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. British Journal of Diabetes & Vascular Disease
9: 69-74
[Abstract]
Amundson, H. A., Butcher, M. K., Gohdes, D., Hall, T. O., Harwell, T. S., Helgerson, S. D., Vanderwood, K. K., for the Montana Cardiovascular Disease and Diabete,
(2009). Translating the Diabetes Prevention Program Into Practice in the General Community: Findings From the Montana Cardiovascular Disease and Diabetes Prevention Program. The Diabetes Educator
35: 209-223
[Abstract][Full Text]
Niswender, K.
(2009). Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?. Clin. Diabetes
27: 60-68
[Abstract][Full Text]
Raz, I., Wilson, P. W.F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., Jacober, S. J.
(2009). Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. Diabetes Care
32: 381-386
[Abstract][Full Text]
Ceriello, A.
(2009). Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D study the answer?. Diabetes Care
32: 521-522
[Full Text]
Amiel, S. A., Cryer, P. E.
(2009). Attenuated Sympathoadrenal Responses, but Not Severe Hypoglycemia, During Aggressive Glycemic Therapy of Early Type 2 Diabetes. Diabetes
58: 515-517
[Full Text]
Siebenhofer-Kroitzsch, A. MD, Horvath, K. MD, Plank, J. MD
(2009). Insulin analogues: too much noise about small benefits. CMAJ
180: 369-370
[Full Text]
Gerstein, H. C.
(2009). Dysglycemia and Cardiovascular Risk in the General Population. Circulation
119: 773-775
[Full Text]
Eddy, D., Schlessinger, L., Kahn, R., Peskin, B., Schiebinger, R.
(2009). Relationship of Insulin Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical Analysis. Diabetes Care
32: 361-366
[Abstract][Full Text]
Khanderia, U., Pop-Busui, R., Eagle, K.
(2009). Authors' Reply. The Annals of Pharmacotherapy
43: 392-393
[Full Text]
Havas, S.
(2009). The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus: Time to Challenge Conventional Wisdom. Arch Intern Med
169: 150-154
[Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol
53: 298-304
[Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation
119: 351-357
[Full Text]
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., Huang, G. D., the VADT Investigators,
(2009). Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. NEJM
360: 129-139
[Abstract][Full Text]
Bhattacharyya, O. K., Estey, E. A., Cheng, A. Y.Y.
(2009). Update on the Canadian Diabetes Association 2008 clinical practice guidelines. cfp
55: 39-43
[Full Text]
Grant, P. J
(2009). The EASD/ADA consensus: trick or treat?. Diabetes and Vascular Disease Research
6: 5-6
Sattar, N.
(2009). Review: PCOS, insulin resistance and long-term risks for diabetes and vascular disease. British Journal of Diabetes & Vascular Disease
9: 15-18
[Abstract]
Gore, M O., McGuire, D. K
(2009). The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diabetes and Vascular Disease Research
6: 53-55
Sherifali, D., Punthakee, Z.
(2009). To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evid. Based Nurs.
12: 4-6
[Full Text]
Kilpatrick, E. S
(2009). Response to Iqbal et al. Ann Clin Biochem 2008;45:504-7. Ann Clin Biochem
46: 86-86
[Full Text]
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S.
(2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association . Diabetes Care
32: 187-192
[Full Text]
Lawler, F. H.
(2009). Reasons to Exercise Caution When Considering a Screening Program for Type 2 Diabetes Mellitus. Mayo Clin Proc.
84: 34-36
[Full Text]
Sheehy, A. M., Coursin, D. B., Gabbay, R. A.
(2009). Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus. Mayo Clin Proc.
84: 38-42
[Full Text]
Previous
